Stock Price Forecast

Dec. 15, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Baudax Bio Inc chart...

About the Company

baudax bio, inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed phase iii clinical trials for the management of moderate to severe pain; and is in the phase iiib clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. the company's early-stage product candidates includes rp1000, an intermediate-acting neuromuscular blocking agent (nmba) that is in phase i clinical trial; and rp2000, an ultrashort-acting nmba, which is in pre-clinical trial; and a reversal agent, as well as dex-in, a proprietary intranasal formulation of dexmedetomidine. the company was incorporated in 2019 and is based in malvern, pennsylvania.

Exchange

OTC MARKETS

$1M

Total Revenue

33

Employees

$0M

Market Capitalization

-0.07

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $BXRX News

Baudax Bio's Nerve Blockade Aces Mid-Stage Study In Surgery Patients

10mon ago, source: Hosted on MSN

Baudax Bio Inc (NASDAQ: BXRX) announced top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in elective surgery patients.In March, Baudax Bio announced ...

Baudax Bio files for bankruptcy a year after halting sales of its pain medicine Anjeso

24d ago, source: The Business Journals

Baudax Bio, a Malvern biopharmaceutical company spun out of Recro Pharma more than four years ago, has filed for U.S. Bankruptcy Court protection. In Thursday's Chapter 11 filing at U.S ...

Baudax Bio Inc Ordinary Shares

11d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Baudax Bio Inc. (BXRXQ)

10d ago, source: Nasdaq

The Dividend History page provides a single page to review all of the aggregated Dividend payment information. Visit our Dividend Calendar: Our partner, Quotemedia, provides the upcoming ex ...

Baudax Bio, Inc. Common Stock (BXRX)

3y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Baudax Bio Inc Ordinary Shares Stock (OTC:BXRX), Insider Trading Activity

24d ago, source: Benzinga.com

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...

Baudax Bio Announces Pricing of $10.0 Million Public Offering

1mon ago, source: ADVFN

Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced ...

Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

1mon ago, source: ADVFN

Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced Gerri Henwood, the Company’s ...

BXRXQ Baudax Bio, Inc.

7mon ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Baudax Bio, Inc. (BXRX)

21d ago, source: Yahoo Finance

Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...